DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0201685 A1 Campbell (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0201685 A1 Campbell (43) Pub US 2011 O2O1685A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0201685 A1 Campbell (43) Pub. Date: Aug. 18, 2011 (54) COMPOSITIONS Publication Classification (75) Inventor: AlistairO O Campbell, Hull (GB) (51) A63L/92Int. Cl. (2006.01) (73) Assignee: Reckitt Benckiser Healthcare A6IPI/00 (2006.01) (E.UK) Limited,Imited, Slougn,Slough, BerkSnureBerkshi A6IPB65D 29/0085/00 (2006.01) (GB) (52) U.S. Cl. ......................................... 514/570; 206/530 (21) Appl. No.: 13/059,260 (57) ABSTRACT (22) PCT Filed: Aug. 18, 2009 An ingestible particulate composition comprises: a) at least e LV9 one compound selected from the group consisting of 2,4- (86). PCT No.: PCT/GBO9/O2O14 dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexitidine, hexylresorcinol, flurbiprofen, lidocaine, S371 (c)(1), benzocaine, ibuprofen, paracetamol, pectin, menthol, and (2), (4) Date: Mar. 25, 2011 benzydamine; and b) one or more bioadhesive materials. Resulting particulate compositions have excellent flow char (30) Foreign Application Priority Data acteristics, dust Suppression, organoleptic properties and sta bility. They are highly suitable for administration direction Aug. 22, 2008 (GB) ................................... O8154056 into a patient's mouth, and ingested to alleviate the symptoms Jan. 9, 2009 (GB) ................................... O900288.2 of a sore throat. Flurbiprofen Xylitol CM170 Mannitol 100SD Carbopol 974P SOdium bicarbonate, Medium Granule. Sieve 1000m Sieve Screen Blend Granulate with Purified Water Tumble Blend for 30minutes High Shear for 3minutes Fluid Bed Dry 500m/h Airflow at 55°C for 15minutes Mill 2000um Serrated COO Mix for Mint FlavOur Screen at 500rpm Peppermint Flavour Aspartame Citric Acid Anhydrous Silicon Dioxide Sieve 1000um Sieve Screen Pack Blend Aluminium Foil Stick Ribbon blend PaCKS for 20minutes Patent Application Publication Aug. 18, 2011 Sheet 1 of 6 US 2011/0201685 A1 Flurbiprofen Xylitol CM170 Mannitol 100SD Carbopol 974P SOdium bicarbonate, Medium Granule. Sieve 1000um Sieve Screen Blend Granulate With Purified Water Tumble Blend for 30minutes High Shear for 3minutes Fluid Bed Dry 500m/h Airflow at 55°C for 15minutes Mill 2000pum Serrated COO Mix for Mint Flavour Screen at 500rpm Peppermint Flavour ASpartame Citric Acid Anhydrous SilicOn Dioxide Sieve 1000pum Sieve SCreen Pack Blend Aluminium Foil Stick Ribbon blend Packs for 20minutes FIG. 1 Patent Application Publication Aug. 18, 2011 Sheet 2 of 6 US 2011/02O1685 A1 Eluate COllection Water Jacket Circulation in (Optional) FIG. 2 Patent Application Publication Aug. 18, 2011 Sheet 3 of 6 US 2011/0201685 A1 Flurbiprofen Release Profiles - Granular Formulation Without Carbopol -- Granular Formulation Containing Carbopol -- LOZenge '83-2 is E 36 - 7.1 664 / 56II 26t 36 0 10 20 30 40 50 60 Time (mins) FIG. 3 Patent Application Publication Aug. 18, 2011 Sheet 4 of 6 US 2011/02O1685 A1 FIG. 4 Patent Application Publication Aug. 18, 2011 Sheet 5 of 6 US 2011/02O1685 A1 MembraCe DOnOr Phase > Clamp Sample Port Aperture ReCeiver Phase Magnetic Flea FIG. 5 Patent Application Publication Aug. 18, 2011 Sheet 6 of 6 US 2011/0201685 A1 -- Tingle n=6 50 —s- Granules Without Carbopol n=6 45 40 35 30 25 E-1 -1 / 20 -1 : 1 - H1 11 - 0 10 20 30 40 50 60 70 Time (min) FIG. 6 US 2011/020 1685 A1 Aug. 18, 2011 COMPOSITIONS pain relief and reduce inflammation in the throat. Although, Some granular compositions are known these do not include a bioadhesive and are rapidly washed away from the throat. 0001. The present invention relates to pharmaceutical 0008. In accordance with a first aspect of the present compositions, and in particular to pharmaceutical composi invention there is provided an ingestible particulate compo tions for the treatment of sore throats. sition comprising: 0002 Sore throats are often treated by sucking a sugar 0009 a) at least one compound selected from the group based lozenge. The lozenge contains at least one compound consisting of 2,4-dichlorobenzyl alcohol, amylmeta which is active against Sore throats. In addition, the Sucking cresol, cetylpyridinium chloride, hexitidine, hexylresor action results in the production of saliva which lubricates the cinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, throat and reduces the pain and discomfort experienced by an paracetamol, pectin, menthol, and benzydamine; and individual. 0.010 b) one or more bioadhesive materials. 0003) A boiled sugar lozenge is a glass or supercooled 0011 Preferably the composition is a flowable particulate, liquid, and at extremely high viscosity has an amorphous by which we mean that it may be poured from a container, e.g. non-crystalline State. In this state, other constituents can be a Sachet, in the manner of Sugar or salt. dissolved or Suspended (colours, flavours, pharmacological 0012 Preferred one or more compounds include but are actives etc). The moisture content of Such a lozenge is low (c. not limited to 2,4-dichlorobenzyl alcohol, amylmetacresol, 2%). Some of this moisture is in a free state, but much of the hexylresorcinol, and flurbiprofen and combinations thereof. moisture is not. This gives a stable chemical and physical In a preferred embodiment the at least one pharmaceutically environment. active compound is selected from flurbiprofen. 0004. However, small increases in the moisture content of 0013 The compositions of the present invention can also such lozenges have the following detrimental effects. The comprise a bicarbonate and/or an organic acid. The compo Viscosity of the glass is reduced, which leads to a gradual sition of the present invention may effervesce in the mouth of cold flow of the lozenge. The presence of free water pro the patient; the bicarbonate, and the organic acid, preferably vides a reaction medium in which accelerated degradation of forming an effervescent couple. added components can occur. Water causes the lozenge to becomesticky and both unattractive and difficult to handle by 0014 Examples of bicarbonates are alkali metal bicarbon packing equipment or by the user. Water is involved in ates Such as Sodium and potassium bicarbonate and alkaline hydrolysis of the disaccharide bond in Sugar, catalysed under earth metal bicarbonates. One or more different bicarbonates acid conditions provided by the typical inclusion of flavour may be used. enhancing organic acids. Cleavage of the disaccharide bond 0015 The bicarbonate when present is suitably present in forms glucose and fructose, which are both more hygroscopic the compositions of the present invention in an amount up to than Sugar (sucrose) and tend to accelerate the absorption of 15%, preferably 5 to 10 wt %; this being the cumulative further water from the surrounding environment. The reduc amount when there is more than one bicarbonate present. tion in the Sugar content compromises the physical hardness 0016 Preferably the organic acid is a carboxylic acid. of the lozenge. In some cases complete liquefaction of the Most preferably it is a polycarboxylic acid. Preferably it has lozenge can occur. As the absorption of water is an accelera 2-5 carboxylic acid groups, more preferably 3-4 carboxylic tive process, low initial water content and the exclusion of acid groups, especially 3. Examples of preferred organic even Small quantities of water from the lozenge environment acids include citric acid, tartaric acid, malic acid, Succinic are important to maximise shelflife. For a medicated lozenge acid, ascorbic acid, adipic acid and fumaric acid. containing pharmaceutical ingredients, the issue of Stability 0017. The molar ratio of organic acid(s): bicarbonate is particularly significant as compared to confectionery loZ (combined weight when more than one is present) can be: enges. For example, a much longer shelf life required of (0.018 3 (acid): 1 (bicarbonate); medicinal products, the health risks associated with chemical (0.019 2 (acid): 1 (bicarbonate); change mediated by increased water content, and the higher 0020 1 (acid): 1 (bicarbonate); value of the goods spoiled. 0021 1 (acid):greater than 1 (bicarbonate); 0005. It would, therefore, be desirable to develop an alter 0022. 1 (acid):at least 1.5 (bicarbonate); native product for treating sore throats which avoids the use of a Sugar-based lozenge. 0023. 1 (acid):at least 2 (bicarbonate); and 0006. In the present invention it is an important object of 0024. 1 (acid):3 (bicarbonate). preferred embodiments to achieve a flowable particulate 0025. A preferred effervescent couple is sodium bicarbon composition which can be administered directly into the ate and citric acid. mouth. The issues Surrounding the oral administration of 0026. Preferably the particulate composition contains at lozenges are quite different to the issues Surrounding the oral least 0.3 wt % organic acid, more preferably at least 1 wt %, administration of particulate compositions, for example loZ more preferably at least 2 wt %, and most preferably 2.5 wt %. enges may simply be Swallowed or more preferably may be These values denote the cumulative amount when there is Sucked. Sucking stimulates the release of saliva, which can more than one organic acid present; and are based on total lubricate the throat reducing the pain and discomfort, or the weight of the composition. perception thereof. When a particulate composition is admin 0027 Suitably the one or more bioadhesive materials is a istered it potentially has a rapid drying effect in the mouth, polymeric or oligomeric compound; preferably a polymeric and there is no Sucking to mitigate that effect. or oligomeric compound having a high molecular weight up 0007. The development objective of this formulation was to several million Daltons. to produce a granule format as a delivery method for Suitable 0028 Preferred one or more bioadhesive materials are pharmaceutically active compounds in order to give localised selected from the group comprising carbomers, such as Car US 2011/020 1685 A1 Aug. 18, 2011 bopol 974P and Carbopol 941 P, xanthan gums, locust bean 0041 Most preferably the single-pack dosage form is gum, alginate, carageenan, or cellulose. Other Suitable car adapted to dispense its contents to a point or Small area within bomers can be used.
Load more

Recommended publications
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Chewable Lozenge Formulation
    Umashankar M S et al. Int. Res. J. Pharm. 2016, 7 (4) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Review Article CHEWABLE LOZENGE FORMULATION- A REVIEW Umashankar M S *, Dinesh S R, Rini R, Lakshmi K S, Damodharan N SRM College of Pharmacy, SRM University, Kattankulathur, India *Corresponding Author Email: [email protected] Article Received on: 11/02/16 Revised on: 13/03/16 Approved for publication: 28/03/16 DOI: 10.7897/2230-8407.07432 ABSTRACT Development of lozenges dated back to 20thcentury and is still remain popular among the consumer and hence it has continued commercial production. Lozenges are palatable solid unit dosage form administrated in the oral cavity. They meant to be dissolved in mouth or pharynx for its local or systemic effect. Lozenge tablets provide several advantages as pharmaceutical formulations however with some disadvantages. Lozenge as a dosage form can be adopted for drug delivery across buccal route, labial route, gingival route and sublingual route. Multiple drugs can also be incorporated in them for chronic illness treatments. Lozenge enables loading of wide range of active ingredients for oral systemic delivery of drugs. Lozenges are available as over the counter medications in the form of caramel based soft lozenges, hard candy lozenges and compressed tablet lozenges containing drugs for sore throat, mouth infection and as mouth fresheners. The rationale behind the use of medicated lozenges as one of the most favored dosage form for the delivery of antitussive drugs. This review focuses various aspects of lozenge formulation providing an insight to the formulation scientist on novel application of lozenge drug delivery system.
    [Show full text]
  • Substantial Equivalence Determination Decision Summary Assay Only Template
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k091024 B. Purpose for Submission: Premarket notification C. Measurand: Methicillin Resistant Staphylococcus aureus (MRSA) D. Type of Test: Detection of MRSA using a selective and differential chromogenic media E. Applicant: bioMérieux, Inc. F. Proprietary and Established Names: chromID™ MRSA Agar G. Regulatory Information: 1. Regulation section: 21 CFR 866.1700 2. Classification: Class II 3. Product code: JSO Culture media, Antimicrobial susceptibility test, excluding Mueller Hinton Agar 1 4. Panel: Microbiology H. Intended Use: 1. Intended use(s): chromID™ MRSA agar is a selective and differential chromogenic medium for the qualitative detection of nasal colonization of methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients and healthcare workers to screen for MRSA colonization. chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 2. Indication(s) for use: The chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 3. Special conditions for use statement(s): Prescription use 4. Special instrument requirements: Not applicable I. Device Description: The chromID™ MRSA agar is translucent and a light tan color. After the plates are inoculated and incubated, colonies growing on the plates will have either a green appearance, which indicates a positive MRSA status or a colorless appearance which indicates a negative MRSA status. The green color is more vivid if the colonies are observed through the agar from the bottom of the plate.
    [Show full text]
  • Adverse Effects and Precautions
    1736 Disinfectants and Preservatives i Amylmetacresoi (BAN, riNN) ..................Preparat ons........ Adverse Effects and Precautions ProprietaryPreparations (details are given in Volume B) The alkyl gallates may cause contact sensitivity and skin Aml!metacreso!; A[ililrnetakrezol: Amylrnet.acreso[; Amylrne.­ AM<InM<;· Multi-ingredient Preparations. Singapore: Esemdent. reactions. ta�resolurn; Amylmetakresol: Amyylirnetakresoli; TaKpe30J1. Effects on the blood. Methaemoglobinaemia associated 6-Pentyl-rn,cresol; S;Methyl.-2-pentylpheooi. Alkyl Gallates with the antoxidants (butylated hydroxyanisole, butylated C1 J1,80= 178.3 hydroxytoluene, and propyl gallate) used to preserve the CAS 1300,94-3. .de Gaiatos alquilo; AnKwnrannalJ:>t. oil in a soybean infant feed fom1ula has been reported.1 UN!! -'-· 05W904P57F: Propyl gallate was suspected of being the most likely cause Dodecyl Gallate because its chemical structure is similar to pyrogallol Pharmacopoeias. In Bur. (see p. vii). (p. 1718.2), a methaemoglobinaemia inducer. Ph. Eur. 8: (Amylmetacresol). A clear or almost clear liquid Dodecilo galatas; Dociecyle,. gallate Dodecylgallat; . de; ..•. I. Nitzan M, et al. Infantile methemoglobinemia caused by food additives. or a solid crystalline mass, colourless or slightly yellow Dodecyi-9Jilat; D(0ec%lis (iallas:. Dodekyyligallaattl; E312; Clin Toxicol 1979; 15: 273-80. when freshly prepared; it darkens or discolours to dark m Galata • de dodecflo; Laury! Gailate; Laurylum Gafikw ; yellow, brownish-yellow, or pink on keeping. F.p. about 22 }logel\vfn rarinar. Preparations degrees. Practically insoluble in water; very soluble in Dodecyi 3,4,5-trihyc;lroxybenzoate. ...................... alcohol and in acetone. Store in non�metallic airtight (details are given in Volume B) C;ul;lje0$=338.4 ProprietaryPreparations containers. Protect from light.
    [Show full text]
  • Study Protocol
    Study Protocol Proposed methodology to measure the impact of GRIP toolkit materials on antibiotic prescribing for URTIs by primary care physicians The method described here illustrates the process for assessment of one specific symptom of upper respiratory tract infection (URTI), sore throat. This has been selected as the Centor criteria may be used to predict the likelihood of a group A streptococcal bacterial infection in patients complaining of acute sore throat1 while other common URTI symptoms are likely to be due to viral infection. This protocol can be adapted for other URTI symptoms. Using this protocol and analysing the collected data can help understand: • The impact of GRIP toolkit materials on antibiotic prescribing in URTIs • Thether current level of antibiotic use is indicated (e.g. in non-high risk patients) Study arms • Control arm: no access to GRIP toolkit materials (n=tbc) • Test arm: full access to GRIP toolkit materials (n=tbc) Test arm: GRIP URTI toolkit preparation prior to assessment If you are part of the control arm and will not be using the toolkit during this assessment, you do not need to read this section. Please go straight to the patient section below. Preparation and planning • Review current personal and colleague management practices when dealing with URTIs, specifically acute sore throat • Ensure each doctor within the test arm has read and understood the toolkit materials • Identify any differences between current practice versus that advised in the GRIP toolkit Defining use of the GRIP toolkit There are four ways the GRIP toolkit can be used by the test arm.
    [Show full text]
  • 2012 Harmonized Tariff Schedule Pharmaceuticals Appendix
    Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5
    [Show full text]
  • Sore Throat in Primary Care Project
    Family Practice, 2015, Vol. 32, No. 3, 263–268 doi:10.1093/fampra/cmv015 Advance Access publication 25 March 2015 Epidemiology Sore throat in primary care project: a clinical score to diagnose viral sore throat Selcuk Mistika,*, Selma Gokahmetoglub, Elcin Balcic, and Fahri A Onukd Downloaded from https://academic.oup.com/fampra/article-abstract/32/3/263/695324 by guest on 31 July 2019 aDepartment of Family Medicine, bDepartment of Microbiology, cDepartment of Public Health, Erciyes University Medical Faculty, Kayseri, Turkey, and dBunyamin Somyurek Family Medicine Centre, Kayseri, Turkey. *Correspondence to Prof. S. Mistik, Department of Family Medicine, Erciyes University Medical Faculty, Kayseri 38039, Turkey; E-mail: [email protected] Abstract Objective. Viral agents cause the majority of sore throats. However, there is not currently a score to diagnose viral sore throat. The aims of this study were (i) to find the rate of bacterial and viral causes, (ii) to show the seasonal variations and (iii) to form a new scoring system to diagnose viral sore throat. Methods. A throat culture for group A beta haemolytic streptococci (GABHS) and a nasopharyngeal swab to detect 16 respiratory viruses were obtained from each patient. Over a period of 52 weeks, a total of 624 throat cultures and polymerase chain reaction analyses were performed. Logistic regression analysis was performed to find the clinical score. Results. Viral infection was found in 277 patients (44.3%), and GABHS infection was found in 116 patients (18.5%). An infectious cause was found in 356 patients (57.1%). Rhinovirus was the most commonly detected infectious agent overall (highest in November, 34.5%), and the highest GABHS rate was in November (32.7%).
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • An Overview of Throat Lozenges and Sprays in the Management of Pharyngitis at Primary Care Level
    REVIEW An overview of throat lozenges and sprays in the management of pharyngitis at primary care level L Wadesango, N Nxumalo, N Schellack School of Pharmacy, Sefako Makgatho Health Sciences University Corresponding author: Lucille Malan ([email protected]) Abstract Pharyngitis, or sore throat, is most commonly a symptom of pharyngeal inflammation and is a common complaint among children, adolescents and adults. Medicinal lozenges and throat sprays form an essential part of the management of pharyngitis or sore throat at primary care level. The pharmacist should ensure that patients understand how to correctly use the throat spray applicator, and not exceed the recommended dosages of these products. This article provides a brief overview of these products and their use in the management of pharyngitis. Keywords: medicinal lozenge, pharyngitis, throat sprays © Medpharm S Afr Pharm J 2019;86(2):17-20 Introduction Symptoms of sore throat Pharyngitis, or sore throat, is most commonly a symptom of Patients reporting to a primary care facility with a sore throat pharyngeal inflammation and is a common complaint among may also present with a number of the following signs and children, adolescents and adults.1 It refers to a painful sensation symptoms1,3-4: 2 and inflammation of the pharynx (back of throat). Viral infections, • Localised pain and mucosal oedema (localised swelling) such as a common cold or influenza, or a substantial bacterial • Husky or hoarse voice infection, such as tonsillitis, are possible causes of a sore throat.3 Most sore throats will resolve without treatment because they are • Odynophagia (painful swallowing when eating or drinking) often associated with a self-limiting viral upper respiratory tract • Dysphagia (having difficulty swallowing) infection (at least 70% are due to less severe cold and flu virus • Dryness of the throat infections).4 Symptomatic relief with throat sprays and lozenges • A scratchy or irritated sensation at the back of the throat is generally advised for patients with uncomplicated pharyngitis.
    [Show full text]
  • Additions to Automation List from 1St March 2012
    Additions to Automation List From 1st March 2012 Aciclovir Susp 200 Mg/5ml Sf Packsize 125 Beclometasone Dipropionate Disks 200 Mcg/Dose With Device Aciclovir Susp 400 Mg/5ml Sf Packsize 100 Packsize 120 Aconite Napellus Tabs 30 C Packsize 125 Beclometasone Dipropionate Disks 400 Mcg/Dose With Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Diskhaler Packsize 120 Pen Packsize 2 Beclometasone Dipropionate Spray 50 Mcg/Dose 200 Dose Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Packsize 1 Syringe Packsize 2 Benzalkonium Chloride Loz 500 Micrograms Sf Packsize 20 Adapalene Cream .1 % Packsize 45 Benzalkonium Chloride Loz 500 Micrograms Sf Packsize 20 Adapalene Gel .1 % Packsize 45 Benzocaine Pdr Packsize 100 Alfacalcidol Inj 2 Mcg/Ml Amp Packsize 10 Benzocaine Pdr Packsize 175 Alfacalcidol Inj 2 Mcg/Ml Amp Packsize 10 Benzoin Tinct Packsize 50 Alfentanil Inj 500 Mcg/Ml Amp Packsize 5 Benzoyl Peroxide Gel 5 % Packsize 50 Alprostadil 1000 Micrograms Sls Urethral Stick Packsize 1 Benzylpenicillin Inj 1200 Mg Vial Packsize 25 Alprostadil 250 Micrograms Sls Urethral Stick Packsize 1 Betaine Anhydrous Pdr Packsize 1 Alprostadil 500 Micrograms Sls Urethral Stick Packsize 1 Biphasic Isophane Insulin Inj 100 Units/Ml Cartridge Packsize 5 Alprostadil Inj 10 Micrograms Sls Continuation Pack Packsize 2 Blackcurrant Syrup Packsize 500 Alprostadil Inj 10 Micrograms Sls Continuation Pack Packsize 2 Bowel Cleansing Solutions Sach Packsize 1 Alprostadil Inj 10 Micrograms Starter Pack With Applicator Bryonia Tabs 30 C Packsize
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Verification and Validation of Analytical Methods for Testing the Levels of Pphcps (Pharmaceutical & Personal Health Care Pr
    Verification and Validation of Analytical Methods for Testing the Levels of PPHCPs (Pharmaceutical & Personal Health Care Products) in treated drinking Water and Sewage Report to the Water Research Commission by Cecilia S. Osunmakinde, Oupa S. Tshabalala, Simiso Dube & Mathew M. Nindi Chemistry Department, University of South Africa WRC Report No. 2094/1/13 ISBN 978-1-4312-0441-0 July 2013 Obtainable from: Water Research Commission Private Bag X03 GEZINA, 0031 [email protected] or download from www.wrc.org.za DISCLAIMER This report has been reviewed by the Water Research Commission (WRC) and approved for publication. Approval does not signify that the contents necessarily reflect the views and policies of the WRC, nor does mention of trade names or commercial products constitute endorsement or recommendation for use. ©Water Research Commission ii Pharmaceutical and personal health care products in treated drinking water and sewage ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ EXECUTIVE SUMMARY ______________________________________________________________________________________ Thousands of metric tons of pharmaceutical and personal care products (PPCPs) are being produced and consumed worldwide per year. This group of emerging contaminants has recently received scrutiny from various communities because their fate and impact on the aquatic environment are not well understood. Since the challenge of water shortages is becoming a reality worldwide, alternatives for protecting the resource such as recycling are being considered. However, such alternatives create concerns relating to the quality of the water especially where the emerging contaminants are not being monitored. There have been reports of the presence of these PPHCPs in water systems although at low concentration levels of microgram to nanogram per litre. It is known though that even at such low concentrations some groups of PPHCPs such as endocrine disrupting compounds may have an adverse effect on aquatic organisms.
    [Show full text]